What is the efficacy of phosphodiesterase type 5 (PDE5) inhibitors for the treatment of premature ejaculation (PE)?

Updated: Jan 15, 2019
  • Author: Samuel G Deem, DO; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print
Answer

A single-blind randomized placebo-controlled clinical study in 100 patients concluded that tadalafil, 5 mg once daily for 6 weeks, was significantly more effective than placebo (P=0.001) and was well tolerated in the treatment of premature ejaculation. [46] Similarly, a meta-analysis of 15 randomized clinical trials suggests that PDE5-Is are significantly more effective than placebo (231 participants; <  0.00001), that there is no difference between PDE5-Is and selective serotonin reuptake inhibitors (SSRIs; 405 participants, = 0.50), and that PDE5-Is combined with an SSRI are significantly more effective than SSRIs alone (521 participants, = 0.001). [47] The use of PDE5 inhibitors for the treatment of premature ejaculation is not approved by the FDA and is considered an off-label use.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!